Progenity Establishes Inflammatory Bowel Disease Clinical Advisory Board
June 17, 2021 07:30 ET
|
Progenity, Inc.
SAN DIEGO, June 17, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), an innovative biotechnology company, today announced the formation of its Inflammatory Bowel Disease Clinical Advisory...
Metacrine to Present at 2021 Jefferies Healthcare Conference
May 26, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Metacrine to Present New Preclinical Data on MET642 in Inflammatory Bowel Disease at Digestive Disease Week 2021 Virtual Meeting
May 19, 2021 08:05 ET
|
Metacrine, Inc.
SAN DIEGO, May 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal...
Positive Signals for Endoscopic and Histologic Response in Patients with Crohn’s Disease Treated with Qu Biologics’ QBECO
January 04, 2021 09:00 ET
|
Qu Biologics, Inc.
VANCOUVER, British Columbia, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel...
Kenneth Rainin Foundation Announces Earlier Funding For Innovator Awards
September 15, 2020 10:55 ET
|
Kenneth Rainin Foundation
Oakland, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- The Kenneth Rainin Foundation announced today that it will open its annual Innovator Awards early to meet researcher needs. The program supports...
UPDATE -- Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 10:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Surrozen Raises $50 Million in Series C Financing to Advance Candidates to Human Clinical Trials
June 19, 2020 07:00 ET
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., June 19, 2020 (GLOBE NEWSWIRE) -- Surrozen Inc., a biotechnology company pioneering a new class of targeted regenerative antibodies, today announced the successful...
Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
March 05, 2020 08:00 ET
|
Innovation Pharmaceuticals Inc.
Active ulcerative colitis targeted; multiple ascending dose design (low, mid, high doses and placebo)Endpoints: clinical remission (Mayo scoring); endoscopic remission; biomarkers, and others ...
PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients
March 02, 2020 09:30 ET
|
PAVmed Inc.
Study to assess EsoCheck as a less invasive, more efficient, and cost-effective alternative to endoscopic biopsies for rapidly emerging allergy-mediated condition which currently requires multiple and...
Innovation Pharmaceuticals Completes Dosing in Phase 1 Trial for New Oral Ulcerative Colitis Drug
January 24, 2020 11:30 ET
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Jan. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today the Company completed dosing in...